OKYO Projected Dividend Yield
Ord (New)/OKYO Pharma Ltd ( NASDAQ : OKYO )OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). Co. is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). Co. is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. 21 YEAR PERFORMANCE RESULTS |
OKYO Dividend History Detail OKYO Dividend News OKYO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |